Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response 

Results, presented simultaneously in oral presentation at ASCO…Read More

You might also be interested in reading VerifyMe signals expanded logistics partnerships and seamless CFO transition amid Q1 revenue decline.